Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Down [Yahoo! Finance]
Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target lowered by analysts at UBS Group AG from $420.00 to $385.00. They now have a "buy" rating on the stock.
Bio-Rad Reports First-Quarter 2024 Financial Results
Molecular Weight Marker Market Forecast Report 2019-2029, Featuring Bio-Rad Laboratories, Merck, New England Biolabs, Promega, QIAGEN, VWR, Takara Bio, HiMedia Laboratories and GeneDireX [Yahoo! Finance]
Bio-Rad’s Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference